Optimising stereotactic body radiotherapy for non-small cell lung cancer and oligometastatic lung disease
Part of Cancer, Lungs & breathing clinical trials.
This study is testing whether giving a higher dose of radiation to the tumour, while still keeping the dose to nearby organs safe, can improve control of the cancer. It's for people with early-stage lung cancer (or a single spot of cancer in the lung from another cancer) who are not suitable for or refuse surgery. The treatment specifically targets tumours that are near the chest wall, where a standard approach might not be safe, and uses a special planning scan to guide the dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with early-stage non-small cell lung cancer or a single spot of cancer in the lung from another cancer
- Your doctor has said you cannot have surgery or you have decided not to have surgery
- You have not had any previous radiation therapy to the chest area
- You are able to have a special CT scan that tracks your breathing
- You are able to give consent
- fitModel_placeholder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a more precise radiation technique (stereotactic body radiotherapy) for early-stage lung cancer or small lung tumors. It aims to reduce side effects by eliminating the usual safety margin around the tumor.
This trial studies a precise, high-dose radiation technique (SBRT) to treat tumors in the lungs. It may help control cancer in people who either have early-stage lung cancer that is not fully operable or have limited lung metastases from other cancers.
This trial tests whether adding precise, high-dose radiation (SBRT) to the targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has shrunk but not disappeared on osimertinib alone.
This trial tests a precise, high-dose radiation treatment aimed at central lung tumors. It may help people who cannot have lung surgery and whose tumors can be safely targeted near sensitive organs.
This study tests a precise radiation technique called SABR to treat cancer that has spread to a few spots. It aims to see if this approach can help control the cancer better than usual treatment, especially for lung, prostate, colorectal, or other solid tumors with limited spread.
This trial compares giving stereotactic ablative radiotherapy as one larger treatment plan versus several smaller plans for people who have only a few cancer spots (or a few spots that are worsening). It may help control metastatic disease while aiming to protect surrounding healthy organs.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.